Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Rasburicase

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Rasburicase - Elitek® For Injection (opens in a new tab)Original source URL: https://globalrph.com/dilution/rasburicase-elitek-for-injection/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/rasburicase-elitek-for-injection/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:50:27.645108+00:00
Source location
div.post-content
Packaged content SHA-256
9114d1af22e878b261254d18d813678d0c12633726d541d6ff54e82198a8be92
Original response SHA-256
ffd3e4f4756e9c506829b8bd81edd384cacff3dc7b3a31e1be062a3d3f910bed
Source body SHA-256
dbbb874f12ccb079c3d6d7124fa8a232c150217b61a9ce832079774756cd6405

Elitek® (rasburicase) for injection, for intravenous use
[ Usual Diluents ] [ Standard Dilution ] [ Storage and Stability ]
DESCRIPTION CLINICAL PHARMACOLOGY INDICATIONS AND USAGE
CONTRAINDICATIONS DOSAGE AND ADMINISTRATION HOW SUPPLIED
WARNINGS
PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information / PDF]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top
NS

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] Return to article top
[Prescribed dose ]
[ 0.2 mg/kg ] [50 ml - total volume] [30 minutes]The recommended dose of Elitek is 0.2 mg/kg as a 30 minute intravenous infusion daily for up to 5 days. Dosing beyond 5 days or administration of more than one course is not recommended.

Reconstitution Procedure:

  • Elitek must be reconstituted with the diluent provided in the carton. The diluent from the glass ampule should be filtered to remove potential Glass particle contamination (GPC)
    prior to adding to the rasburicase vial for reconstitution. Do not filter the reconstituted product.
  • Reconstitute the 1.5 mg vial of Elitek with 1 mL of diluent. Reconstitute the 7.5 mg vial of Elitek with 5 mL of diluent. Mix by swirling gently. Do not shake or vortex.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard solution if particulate matter is visible or product is discolored.

Further Dilution and Administration:

  • Do not administer Elitek as a bolus injection. Administer Elitek as an intravenous infusion only
  • Inject the calculated dose of reconstituted Elitek solution into an infusion bag containing the appropriate volume of 0.9% sterile sodium chloride, to achieve a final total volume of 50 mL.
  • Infuse over 30 minutes through a separate line or flush line with at least 15 mL of normal saline prior to and after Elitek infusion.
  • Do not use filters during infusion of reconstituted Elitek drug product.
  • Store reconstituted or diluted solution at 2-8°C.
  • Discard unused product solution 24 hours following reconstitution.

Stability data:
Stability
Refrigerated		 Stability
Room Temp.		 Reconstituted
Vial/Powder		 Notes
24 hours - 24 hours The lyophilized drug product and the diluent for reconstitution should be stored at 2-8°C (36-46°F). Do not freeze. Protect from light.

Store reconstituted or diluted solution at 2-8°C.
Discard unused product solution 24 hours following reconstitution.

WARNINGS Return to article top
See warnings and precautions below.
WARNING:
  • WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS
    Hypersensitivity ReactionsElitek® can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue Elitek in patients who experience a serious hypersensitivity reaction [see package insert - CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.1), ADVERSE REACTIONS (6.2)].
  • HemolysisDo not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue Elitek in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek [see package insert - CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.2)].
  • MethemoglobinemiaElitek can result in methemoglobinemia in some patients. Immediately and permanently discontinue Elitek in patients developing methemoglobinemia [see package insert - CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.3)].
  • Interference with Uric Acid MeasurementsElitek enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in pre-chilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection

DESCRIPTION Return to article top
Description:
Elitek (rasburicase) is a recombinant urate-oxidase produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.Rasburicase is a tetrameric protein with identical subunits. Each subunit is made up of a single 301 amino acid polypeptide chain with a molecular mass of about 34 kDa. The drug product is a sterile, white to off-white, lyophilized powder intended for intravenous administration following reconstitution with a diluent. Elitek is supplied in 3 mL and 10 mL colorless, glass vials containing rasburicase at a concentration of 1.5 mg/mL after reconstitution.

Elitek 1.5 mg presentation contains 1.5 mg rasburicase, 10.6 mg mannitol, 15.9 mg L-alanine, between 12.6 and 14.3 mg of dibasic sodium phosphate (lyophilized powder), and a diluent (1 mL Water for Injection, USP, and 1 mg Poloxamer 188).

Elitek 7.5 mg presentation contains 7.5 mg of rasburicase, 53 mg mannitol, 79.5 mg L-alanine, and between 63 and 71.5 mg dibasic sodium phosphate (lyophilized powder) and a diluent (5 mL Water for Injection, USP, and 5 mg Poloxamer 188).

CLINICAL PHARMACOLOGY: Return to article top
Mechanism of Action:
In humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzes enzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite (allantoin).

INDICATIONS AND USAGE Return to article top
INDICATIONS AND USAGE:
Elitek® is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.Limitation of use: Elitek is indicated only for a single course of treatment.

USE IN SPECIFIC POPULATIONS
Pregnancy: May cause fetal harm. Use only if the potential benefit to the mother justifies the potential risk to the fetus (8.1).
Nursing Mothers: Discontinue nursing or Elitek taking into account the importance of the drug to the mother (8.3). [Drug information / PDF]

CONTRAINDICATIONS Return to article top
Contraindications:
Elitek is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase [see BOXED WARNING, WARNINGS AND PRECAUTIONS (5)].Elitek is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD) [see BOXED WARNING, WARNINGS AND PRECAUTIONS (5.2)].

PRECAUTIONS Return to article top
WARNINGS:

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS
Hypersensitivity Reactions

Elitek® can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue Elitek in patients who experience a serious hypersensitivity reaction [see package insert - CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.1), ADVERSE REACTIONS (6.2)].

Hemolysis

Do not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue Elitek in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek [see package insert - CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.2)].

Methemoglobinemia

Elitek can result in methemoglobinemia in some patients. Immediately and permanently discontinue Elitek in patients developing methemoglobinemia [see package insert - CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.3)].

Interference with Uric Acid Measurements

Elitek enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in pre-chilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection
[Drug information / PDF]

DOSAGE AND ADMINISTRATION Return to article top
DOSAGE AND ADMINISTRATION:
Dosage
The recommended dose of Elitek is 0.2 mg/kg as a 30 minute intravenous infusion daily for up to 5 days. Dosing beyond 5 days or administration of more than one course is not recommended.Reconstitution Procedure:
  • Elitek must be reconstituted with the diluent provided in the carton. The diluent from the glass ampule should be filtered to remove potential Glass particle contamination (GPC)
    prior to adding to the rasburicase vial for reconstitution. Do not filter the reconstituted product.
  • Reconstitute the 1.5 mg vial of Elitek with 1 mL of diluent. Reconstitute the 7.5 mg vial of Elitek with 5 mL of diluent. Mix by swirling gently. Do not shake or vortex.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard solution if particulate matter is visible or product is discolored.

Further Dilution and Administration:

  • Do not administer Elitek as a bolus injection. Administer Elitek as an intravenous infusion only
  • Inject the calculated dose of reconstituted Elitek solution into an infusion bag containing the appropriate volume of 0.9% sterile sodium chloride, to achieve a final total volume of 50 mL.
  • Infuse over 30 minutes through a separate line or flush line with at least 15 mL of normal saline prior to and after Elitek infusion.
  • Do not use filters during infusion of reconstituted Elitek drug product.
  • Store reconstituted or diluted solution at 2-8°C.
  • Discard unused product solution 24 hours following reconstitution.

HOW SUPPLIED Return to article top
DOSAGE FORMS AND STRENGTHS:

For injection, 1.5 mg, lyophilized powder in single-dose vial
For injection, 7.5 mg lyophilized powder in single-dose vial

Storage and Stability Return to article top
How Supplied

NDC 0024-5150-10: One carton contains 3 single-dose vials each containing 1.5 mg of rasburicase and 3 ampules each containing 1 mL diluent.

NDC 0024-5151-75: One carton contains 1 single-dose vial containing 7.5 mg of rasburicase and 1 ampule containing 5 mL diluent.

Storage and Handling

The lyophilized drug product and the diluent for reconstitution should be stored at 2-8°C (36-46°F). Do not freeze. Protect from light.

Manufactured by:
sanofi-aventis U.S. LLC
Bridgewater, NJ 08807
U.S. License No. 1752

© 2016 sanofi-aventis U.S. LLC

Revised: 7/2016

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
monitor_or_titrate
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      rasburicase
      Source IDH51-DBA8379DD069D664F55472AB
      Generic name
      Rasburicase
      Source IDH51-1931ADE1D651EFEB781F538A
      Class
      Other intravenous medications
      Source IDH51-55CB126E30D71F9B288D240A
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-46391F49C1DE32DE948A8900
      Primary uses
      1. A specialized IV indication that requires confirmation in the current exact-product label and applicable specialty guidance.
        Source IDH51-D578A66812A6682A0200B8D2
      Mechanism
      Recombinant urate oxidase converts uric acid to the more soluble metabolite allantoin.
      Source IDH51-D64612789931369F24A57916
      Mechanism level
      drug_specific
      Source IDH51-9219DFE84AC6C52B5E12C175
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-54C12A48D821817DE86759CA
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-F0F2C264B72454952289C396
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply.
      Source IDH51-41CBA01A25C94FDF9EBF2296
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-01205B6E1143098A524A687B
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-FA02FF30DDE11F4960919AFB
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-7B1F9AD3D8D3913A4797806C
      Legacy title
      Rasburicase
      Source IDH51-C60C05E8E55B4D572BB8C6E6
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-4C7DEFA88D5D37B7ECACF6F5
      Search text
      Rasburicase Other intravenous medications Legacy GlobalRPh directory entry A specialized IV indication that requires confirmation in the current exact-product label and applicable specialty guidance. Recombinant urate oxidase converts uric acid to the more soluble metabolite allantoin. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-AE7A4ACCF93FFAF77DC52AE3
      Official access mode
      none
      Source IDH51-E21669875B5BE2D003FA7BAF
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-B614B3369F6B70E8F51C147F

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      monitor_or_titrate
      Source IDH51-8AFE26BFBB7B4E07FB642C82
      Summary
      Renal function materially affects toxicity, monitoring, or titration even when a fixed table may not apply.
      Source IDH51-DE885DF3925EFB3F56863E84
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-08BE0B760CE17B49D3B27968

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-AB92077ACA0DEBC81CFE3F28

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-C78C3851861116BFD34446AF
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      rasburicase
      Source IDH51-DD4456A865F7B6A32C9452A7
      Legacy title
      Rasburicase
      Source IDH51-12C8DB75C6C9344B22DCD63A
      Generic name
      Rasburicase
      Source IDH51-8FB23308938EC326FA38BBEE
      Class
      Other intravenous medications
      Source IDH51-4D4B3F8E917C985373E8579D
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-1C5F01E8E023F3C03635421E
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-5330D01C7237D69FDFEBD49A
      Populations
      1. Population not yet normalized
        Source IDH51-655B7361BEE5CE225C7C5FF5
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-EB87AC8D1EB71B3DF8502734
      High alert
      false
      Source IDH51-13C089E4F73E1050E946C53F
      Hazardous
      false
      Source IDH51-193E12850C3599422CA98BC6
      Status
      Legacy migration
      Source IDH51-BFDB68B9BC324ED0F4A96937
      Version added
      Legacy
      Source IDH51-73CC4C383A09D3C12E778470
      Sources
      LabelUrlKind
      Source IDH51-78DA5B65C9D1FCDBFFEFD3FE
      GlobalRPh legacy IV dilution monograph
      Source IDH51-6A9CABB90BC80A2559F2EE32
      		legacy:auto
      Source IDH51-B85388BEDA369A0791980538
      		Legacy
      Source IDH51-6F1032CDF9EEEE7B3667BED8
      Clinical release verification
      Audit version
      3.4
      Source IDH51-BAA8273C8060FAB5D8289209
      Audited on
      2026-08-30
      Source IDH51-6B75E99540FD26D008B8F758
      Level
      red
      Source IDH51-87D0FB2D2EE157292CA53C02
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-71DA6D288B1EF36B684D9A96
      Exact current label candidate
      false
      Source IDH51-7EDFFA4157890124A5D55204
      Reference url count
      0
      Source IDH51-C94F749771C8FE334BD8B2B4
      Broken reference count
      0
      Source IDH51-5D321F8F3F028CAD7AD86DFE
      Point of use confirmation required
      true
      Source IDH51-9810DC38D0BF33F215430DA4
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-C743531E8CF88A8D1C914C93

      Dosing source fields

      Id
      rasburicase
      Source IDH51-4D63152CE95A30A0D65A829F
      Generic name
      Rasburicase
      Source IDH51-F09D03DFA7D370D3E51DC21B
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-AEC3A142935D7305BAD44EBF
      Package insert
      Query name
      Rasburicase
      Source IDH51-84B0BCDDCF57C071A1683128
      Product and route must match
      true
      Source IDH51-4830D5AB481A2B09E1ACB023
      Live current label enabled
      false
      Source IDH51-64D27D11607C81973970E4FA
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-9469CF7D4E5251F3E4F9DDF8
      Direct official label access enabled
      true
      Source IDH51-749F948F0356BE3070453586
      Outbound server request required
      false
      Source IDH51-92325F45EB6CFA9E85376460
      Local summary status
      not_bundled
      Source IDH51-2DE1EEC6B13AE5FF73A5AFBC
      Clinical review
      Locally normalized
      false
      Source IDH51-AD230934A6F88189C7DE25B6
      Reviewed
      2026-08-29
      Source IDH51-EEC25244A7700D72ADD05B8B
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-A1D4BBF29E834A0E4F0F3854
      Clinical release verification
      Audit version
      3.4
      Source IDH51-917014EA2D8FC82A8645ED74
      Audited on
      2026-08-30
      Source IDH51-8131E7664FD688D91D921A68
      Level
      red
      Source IDH51-C030DA7C5D1B1FD5C9B27274
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-D2E42D7CEE3401197F42BCAC
      Exact current label candidate
      false
      Source IDH51-DE9D52C3E947D4F0A9E80EE0
      Reference url count
      0
      Source IDH51-420AEDDB2076AC392A5D3967
      Broken reference count
      0
      Source IDH51-7D31E5F0C5BDF9950AEFF27C
      Point of use confirmation required
      true
      Source IDH51-EB96C8646DF8E73D585533FF
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-73D40AADF53B8A4E1D72DB61
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      rasburicase
      Source IDH51-947A6DDAFCD973F87F21D101
      Name
      Rasburicase
      Source IDH51-DA4D3735B37A34B1D04024F0
      Therapeutic class
      Other intravenous medications
      Source IDH51-258D8A4A5DDBA117699C5C7B
      Review version
      3.1
      Source IDH51-654FB2B7765D6890B3EC8585
      Review date
      2026-08-30
      Source IDH51-575D31966F1768B971C0E8DC
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-8E89B29A2A7642D1537A9775
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-3DD470F376016EB5CF0DFAAE
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-783E4A71F671D1364E2DEFFB
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-DAF1E6112D0E5088B2A9FCA7
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-DF8CBB6EBA5F3BE9B25839EC
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-00CCD3339DD4DCC07DB1EE20
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-13FA74FCA91B2081F8624D63
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-80D188B60643498322EDC1EE
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-0E161DD15F2F3E53FD67B8D3
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-88C2B905EC60920E6D75AED2
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-CE16C34977D6C3B2756F33F1
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-336B8283A0A385FFFE99AEAA
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-846E3A0635B9C23F9E7C958C
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-6BAAE1AA8E817068201EA9A2
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-96FC8EB03033BD75E6A9A020
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-E295D637B1B0AD3FA506671E
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-6D89FFC2ED74C4C998E53D57
      Adult dosing range
      Primary
      not_found
      Source IDH51-43B6F8481EEBDCFD7720002E
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-03865C19DE7071B642A8F4DA
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-F5C50FF21CF0E253048733A0
      Infusion time
      Primary
      not_found
      Source IDH51-93233689A4B2CABF42560698
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-5AE4AE9088F16BD27DD384B5
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-4D064B153852D17F2EB785CA
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-2A10A4196DCE52A6CFF47300
      Guide generation allowed
      false
      Source IDH51-55E788E549F9A7262440F22A
      Pediatric
      Applicability
      not_established
      Source IDH51-F1DCA3A463871114B4DE2426
      Guide generation allowed
      false
      Source IDH51-4497B9ACF95B19F5AA4E076D
      Neonatal
      Applicability
      not_established
      Source IDH51-E5D9B52F32AF637EA907E3B2
      Guide generation allowed
      false
      Source IDH51-2F14DA3790BF886AC1A61009
      Route presence
      Structured dilution
      false
      Source IDH51-6D4160A76BACD07452474005
      Iv push
      false
      Source IDH51-9E78F4F19576592AC93C1C19
      Continuous infusion
      true
      Source IDH51-CB5A088CA22720F80F3B080A
      Pediatric source
      false
      Source IDH51-04ADFA3631F2151A52632115
      Neonatal source
      false
      Source IDH51-9183FDB9673D26F6D1F683EE
      Legacy reference
      Status
      not_available
      Source IDH51-11A1DC43D8FD08B01F570A67
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-746BF89B49C5CA1EA358B3F7
      Source files
      1. catalog.json
        Source IDH51-5F37FD8687CB668918AA98CF
      2. dosing.json
        Source IDH51-122651CB9ED3349BCAED15AE
      3. legacy-map.json
        Source IDH51-EB8348276681641148648817
      4. review-queue.json
        Source IDH51-13D837D58EA2E21ED5F7A514
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-57F7B45B2525001FC32AE373
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-DD4456A865F7B6A32C9452A7catalog.json
      /records/215/id      		Historical; current review incomplete
      H51-12C8DB75C6C9344B22DCD63Acatalog.json
      /records/215/legacy_title      		Historical; current review incomplete
      H51-8FB23308938EC326FA38BBEEcatalog.json
      /records/215/generic_name      		Historical; current review incomplete
      H51-4D4B3F8E917C985373E8579Dcatalog.json
      /records/215/class      		Historical; current review incomplete
      H51-1C5F01E8E023F3C03635421Ecatalog.json
      /records/215/subclass      		Historical; current review incomplete
      H51-5330D01C7237D69FDFEBD49Acatalog.json
      /records/215/summary      		Historical; current review incomplete
      H51-AB92077ACA0DEBC81CFE3F28catalog.json
      /records/215/warnings/0      		Historical; current review incomplete
      H51-C78C3851861116BFD34446AFcatalog.json
      /records/215/stability_notes/0      		Historical; current review incomplete
      H51-655B7361BEE5CE225C7C5FF5catalog.json
      /records/215/populations/0      		Historical; current review incomplete
      H51-EB87AC8D1EB71B3DF8502734catalog.json
      /records/215/evidence_tier      		Historical; current review incomplete
      H51-13C089E4F73E1050E946C53Fcatalog.json
      /records/215/high_alert      		Historical; current review incomplete
      H51-193E12850C3599422CA98BC6catalog.json
      /records/215/hazardous      		Historical; current review incomplete
      H51-BFDB68B9BC324ED0F4A96937catalog.json
      /records/215/status      		Historical; current review incomplete
      H51-A46EBE32D762962DC50EF492catalog.json
      /records/215/reviewed      		Historical; current review incomplete
      H51-73CC4C383A09D3C12E778470catalog.json
      /records/215/version_added      		Historical; current review incomplete
      H51-78DA5B65C9D1FCDBFFEFD3FEcatalog.json
      /records/215/sources/0      		Historical; current review incomplete
      H51-6A9CABB90BC80A2559F2EE32catalog.json
      /records/215/sources/0/label      		Historical; current review incomplete
      H51-B85388BEDA369A0791980538catalog.json
      /records/215/sources/0/url      		Historical; current review incomplete
      H51-6F1032CDF9EEEE7B3667BED8catalog.json
      /records/215/sources/0/kind      		Historical; current review incomplete
      H51-BAA8273C8060FAB5D8289209catalog.json
      /records/215/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-6B75E99540FD26D008B8F758catalog.json
      /records/215/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-87D0FB2D2EE157292CA53C02catalog.json
      /records/215/clinical_release_verification/level      		Historical; current review incomplete
      H51-71DA6D288B1EF36B684D9A96catalog.json
      /records/215/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-7EDFFA4157890124A5D55204catalog.json
      /records/215/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-24F42E085BDD3851BA5D9C6Acatalog.json
      /records/215/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-BC30C0A53DF219428724BDF9catalog.json
      /records/215/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-C34E4A4854772EC4B42829CFcatalog.json
      /records/215/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-C94F749771C8FE334BD8B2B4catalog.json
      /records/215/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-5D321F8F3F028CAD7AD86DFEcatalog.json
      /records/215/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-9810DC38D0BF33F215430DA4catalog.json
      /records/215/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-C743531E8CF88A8D1C914C93catalog.json
      /records/215/clinical_release_verification/note      		Historical; current review incomplete
      H51-7720A059467F50956B881C80catalog.json
      /records/215/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-4D63152CE95A30A0D65A829Fdosing.json
      /records/215/id      		Historical; current review incomplete
      H51-F09D03DFA7D370D3E51DC21Bdosing.json
      /records/215/generic_name      		Historical; current review incomplete
      H51-AEC3A142935D7305BAD44EBFdosing.json
      /records/215/coverage_status      		Historical; current review incomplete
      H51-84B0BCDDCF57C071A1683128dosing.json
      /records/215/package_insert/query_name      		Historical; current review incomplete
      H51-87C1A89E12A3ACDB8BE28B5Fdosing.json
      /records/215/package_insert/preferred_setid      		Historical; current review incomplete
      H51-4830D5AB481A2B09E1ACB023dosing.json
      /records/215/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-64D27D11607C81973970E4FAdosing.json
      /records/215/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-9469CF7D4E5251F3E4F9DDF8dosing.json
      /records/215/package_insert/source_priority      		Historical; current review incomplete
      H51-749F948F0356BE3070453586dosing.json
      /records/215/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-92325F45EB6CFA9E85376460dosing.json
      /records/215/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-2DE1EEC6B13AE5FF73A5AFBCdosing.json
      /records/215/package_insert/local_summary_status      		Historical; current review incomplete
      H51-8AFE26BFBB7B4E07FB642C82dosing.json
      /records/215/renal/classification      		Historical; current review incomplete
      H51-DE885DF3925EFB3F56863E84dosing.json
      /records/215/renal/summary      		Historical; current review incomplete
      H51-08BE0B760CE17B49D3B27968dosing.json
      /records/215/renal/method_note      		Historical; current review incomplete
      H51-AD230934A6F88189C7DE25B6dosing.json
      /records/215/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-EEC25244A7700D72ADD05B8Bdosing.json
      /records/215/clinical_review/reviewed      		Historical; current review incomplete
      H51-A1D4BBF29E834A0E4F0F3854dosing.json
      /records/215/clinical_review/status      		Historical; current review incomplete
      H51-917014EA2D8FC82A8645ED74dosing.json
      /records/215/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-8131E7664FD688D91D921A68dosing.json
      /records/215/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-C030DA7C5D1B1FD5C9B27274dosing.json
      /records/215/clinical_release_verification/level      		Historical; current review incomplete
      H51-D2E42D7CEE3401197F42BCACdosing.json
      /records/215/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-DE9D52C3E947D4F0A9E80EE0dosing.json
      /records/215/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-98473150692E32DC060FA374dosing.json
      /records/215/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-94E59CFA4C48A4C86A93F177dosing.json
      /records/215/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-134579E3668846907FE9E9AEdosing.json
      /records/215/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-420AEDDB2076AC392A5D3967dosing.json
      /records/215/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-7D31E5F0C5BDF9950AEFF27Cdosing.json
      /records/215/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-EB96C8646DF8E73D585533FFdosing.json
      /records/215/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-73D40AADF53B8A4E1D72DB61dosing.json
      /records/215/clinical_release_verification/note      		Historical; current review incomplete
      H51-66F468097CCC0B6659F0BF3Bdosing.json
      /records/215/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-DBA8379DD069D664F55472ABfirst-look-v5.1.json
      /records/215/id      		Historical; current review incomplete
      H51-1931ADE1D651EFEB781F538Afirst-look-v5.1.json
      /records/215/generic_name      		Historical; current review incomplete
      H51-55CB126E30D71F9B288D240Afirst-look-v5.1.json
      /records/215/class      		Historical; current review incomplete
      H51-46391F49C1DE32DE948A8900first-look-v5.1.json
      /records/215/subclass      		Historical; current review incomplete
      H51-D578A66812A6682A0200B8D2first-look-v5.1.json
      /records/215/primary_uses/0      		Historical; current review incomplete
      H51-D64612789931369F24A57916first-look-v5.1.json
      /records/215/mechanism      		Historical; current review incomplete
      H51-9219DFE84AC6C52B5E12C175first-look-v5.1.json
      /records/215/mechanism_level      		Historical; current review incomplete
      H51-54C12A48D821817DE86759CAfirst-look-v5.1.json
      /records/215/basic_dosing_orientation      		Historical; current review incomplete
      H51-F0F2C264B72454952289C396first-look-v5.1.json
      /records/215/administration_orientation      		Historical; current review incomplete
      H51-41CBA01A25C94FDF9EBF2296first-look-v5.1.json
      /records/215/renal_and_population_orientation      		Historical; current review incomplete
      H51-01205B6E1143098A524A687Bfirst-look-v5.1.json
      /records/215/key_safety_orientation/0      		Historical; current review incomplete
      H51-FA02FF30DDE11F4960919AFBfirst-look-v5.1.json
      /records/215/coverage_path      		Historical; current review incomplete
      H51-7B1F9AD3D8D3913A4797806Cfirst-look-v5.1.json
      /records/215/coverage_path_label      		Historical; current review incomplete
      H51-3409718726A0B21325CF4F56first-look-v5.1.json
      /records/215/official_label_url      		Historical; current review incomplete
      H51-C60C05E8E55B4D572BB8C6E6first-look-v5.1.json
      /records/215/legacy_title      		Historical; current review incomplete
      H51-4C7DEFA88D5D37B7ECACF6F5first-look-v5.1.json
      /records/215/review_note      		Historical; current review incomplete
      H51-AE7A4ACCF93FFAF77DC52AE3first-look-v5.1.json
      /records/215/search_text      		Historical; current review incomplete
      H51-D62DC67770DF9636E3895B88first-look-v5.1.json
      /records/215/official_search_url      		Historical; current review incomplete
      H51-E21669875B5BE2D003FA7BAFfirst-look-v5.1.json
      /records/215/official_access_mode      		Historical; current review incomplete
      H51-42ABBB564AB73E67493E8772first-look-v5.1.json
      /records/215/official_access_url      		Historical; current review incomplete
      H51-4F14C0D8BA6B0947D87AEFAAfirst-look-v5.1.json
      /records/215/official_search_query      		Historical; current review incomplete
      H51-B614B3369F6B70E8F51C147Ffirst-look-v5.1.json
      /records/215/official_access_reason      		Historical; current review incomplete
      H51-947A6DDAFCD973F87F21D101preparation-assessments-v3.8.json
      /215/id      		Historical; current review incomplete
      H51-DA4D3735B37A34B1D04024F0preparation-assessments-v3.8.json
      /215/name      		Historical; current review incomplete
      H51-85308462340D4818A65FF0C3preparation-assessments-v3.8.json
      /215/brands      		Historical; current review incomplete
      H51-258D8A4A5DDBA117699C5C7Bpreparation-assessments-v3.8.json
      /215/therapeutic_class      		Historical; current review incomplete
      H51-654FB2B7765D6890B3EC8585preparation-assessments-v3.8.json
      /215/review_version      		Historical; current review incomplete
      H51-575D31966F1768B971C0E8DCpreparation-assessments-v3.8.json
      /215/review_date      		Historical; current review incomplete
      H51-8E89B29A2A7642D1537A9775preparation-assessments-v3.8.json
      /215/release_status      		Historical; current review incomplete
      H51-3DD470F376016EB5CF0DFAAEpreparation-assessments-v3.8.json
      /215/market_status/status      		Historical; current review incomplete
      H51-783E4A71F671D1364E2DEFFBpreparation-assessments-v3.8.json
      /215/market_status/basis      		Historical; current review incomplete
      H51-DAF1E6112D0E5088B2A9FCA7preparation-assessments-v3.8.json
      /215/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-DF8CBB6EBA5F3BE9B25839ECpreparation-assessments-v3.8.json
      /215/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-00CCD3339DD4DCC07DB1EE20preparation-assessments-v3.8.json
      /215/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-13FA74FCA91B2081F8624D63preparation-assessments-v3.8.json
      /215/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-80D188B60643498322EDC1EEpreparation-assessments-v3.8.json
      /215/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-0E161DD15F2F3E53FD67B8D3preparation-assessments-v3.8.json
      /215/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-88C2B905EC60920E6D75AED2preparation-assessments-v3.8.json
      /215/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-CE16C34977D6C3B2756F33F1preparation-assessments-v3.8.json
      /215/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-336B8283A0A385FFFE99AEAApreparation-assessments-v3.8.json
      /215/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-86BC6F35BD037ABC5B405C5Apreparation-assessments-v3.8.json
      /215/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-2D5A0C9CE50C999EB9B0B5F9preparation-assessments-v3.8.json
      /215/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-7501BBD0EFC799DAEB00BEE9preparation-assessments-v3.8.json
      /215/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-86A6C4A47E808808AAD7483Dpreparation-assessments-v3.8.json
      /215/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-846E3A0635B9C23F9E7C958Cpreparation-assessments-v3.8.json
      /215/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-B5195EDF7AE6FE3BADBE2924preparation-assessments-v3.8.json
      /215/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-6BAAE1AA8E817068201EA9A2preparation-assessments-v3.8.json
      /215/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-96FC8EB03033BD75E6A9A020preparation-assessments-v3.8.json
      /215/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-E295D637B1B0AD3FA506671Epreparation-assessments-v3.8.json
      /215/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-6D89FFC2ED74C4C998E53D57preparation-assessments-v3.8.json
      /215/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-43B6F8481EEBDCFD7720002Epreparation-assessments-v3.8.json
      /215/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-03865C19DE7071B642A8F4DApreparation-assessments-v3.8.json
      /215/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-F5C50FF21CF0E253048733A0preparation-assessments-v3.8.json
      /215/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-93233689A4B2CABF42560698preparation-assessments-v3.8.json
      /215/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-5AE4AE9088F16BD27DD384B5preparation-assessments-v3.8.json
      /215/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-4D064B153852D17F2EB785CApreparation-assessments-v3.8.json
      /215/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-2A10A4196DCE52A6CFF47300preparation-assessments-v3.8.json
      /215/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-55E788E549F9A7262440F22Apreparation-assessments-v3.8.json
      /215/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-F1DCA3A463871114B4DE2426preparation-assessments-v3.8.json
      /215/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-4497B9ACF95B19F5AA4E076Dpreparation-assessments-v3.8.json
      /215/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-E5D9B52F32AF637EA907E3B2preparation-assessments-v3.8.json
      /215/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-2F14DA3790BF886AC1A61009preparation-assessments-v3.8.json
      /215/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-6D4160A76BACD07452474005preparation-assessments-v3.8.json
      /215/route_presence/structured_dilution      		Historical; current review incomplete
      H51-9E78F4F19576592AC93C1C19preparation-assessments-v3.8.json
      /215/route_presence/iv_push      		Historical; current review incomplete
      H51-CB5A088CA22720F80F3B080Apreparation-assessments-v3.8.json
      /215/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-04ADFA3631F2151A52632115preparation-assessments-v3.8.json
      /215/route_presence/pediatric_source      		Historical; current review incomplete
      H51-9183FDB9673D26F6D1F683EEpreparation-assessments-v3.8.json
      /215/route_presence/neonatal_source      		Historical; current review incomplete
      H51-11A1DC43D8FD08B01F570A67preparation-assessments-v3.8.json
      /215/legacy_reference/status      		Historical; current review incomplete
      H51-746BF89B49C5CA1EA358B3F7preparation-assessments-v3.8.json
      /215/label_resolution/status      		Historical; current review incomplete
      H51-5F37FD8687CB668918AA98CFpreparation-assessments-v3.8.json
      /215/source_files/0      		Historical; current review incomplete
      H51-122651CB9ED3349BCAED15AEpreparation-assessments-v3.8.json
      /215/source_files/1      		Historical; current review incomplete
      H51-EB8348276681641148648817preparation-assessments-v3.8.json
      /215/source_files/2      		Historical; current review incomplete
      H51-13D837D58EA2E21ED5F7A514preparation-assessments-v3.8.json
      /215/source_files/3      		Historical; current review incomplete
      H51-57F7B45B2525001FC32AE373preparation-assessments-v3.8.json
      /215/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top